In Brief: Coulter Corp.
This article was originally published in The Gray Sheet
Executive SummaryCoulter Corp.: Anticipates approval "very soon" for its Coulter HIV-1 p24 antigen assay for use in blood donor screening. The Miami-based firm says it has submitted all the data requested by the agency since receiving its "approvable letter" in August 1995 ("The Gray Sheet" Aug. 14, 1995, p. 12), including stability and product labeling information. Ortho Diagnostic Systems has exclusive worldwide rights to market the test for screening indications. The test will be run on Ortho's automated Summit system, which already is used with microplate format screening tests for HIV-1, Hepatitis and other diseases...
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.